Phathom Pharmaceuticals Stock (NASDAQ:PHAT)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$7.82

52W Range

$6.07 - $19.71

50D Avg

$12.40

200D Avg

$12.14

Market Cap

$509.41M

Avg Vol (3M)

$1.27M

Beta

0.72

Div Yield

-

PHAT Company Profile


Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

452

IPO Date

Oct 25, 2019

Website

PHAT Performance


PHAT Financial Summary


Dec 23Dec 22Dec 21
Revenue$682.00K--
Operating Income$-167.31M$-172.44M$-135.08M
Net Income-$-223.01M$-148.09M
EBITDA$-167.31M$-170.42M$-137.09M
Basic EPS-$-5.70$-4.00
Diluted EPS-$-5.70$-4.00

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Nov 10, 24 | 3:54 AM
Q2 24Aug 10, 24 | 2:52 PM
Q1 24May 09, 24 | 12:00 AM

Peer Comparison


TickerCompany
CGEMCullinan Oncology, Inc.
BPMCBlueprint Medicines Corporation
DAWNDay One Biopharmaceuticals, Inc.
INZYInozyme Pharma, Inc.
XFORX4 Pharmaceuticals, Inc.
CNSPCNS Pharmaceuticals, Inc.
KNSAKiniksa Pharmaceuticals, Ltd.
IMMXImmix Biopharma, Inc.
ABOSAcumen Pharmaceuticals, Inc.
GPCRStructure Therapeutics Inc.
TERNTerns Pharmaceuticals, Inc.
HEPAHepion Pharmaceuticals, Inc.
LYRALyra Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals, Inc.